Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Genetic toxicity in vitro
Description of key information
In a Bacterial reverse mutation assay / Ames test, conducted according to OECD 471 and in compliance with GLP, the Salmonella typhimurium strains TA 100, TA 1535 and E. coli WP2 uvr A, although not TA 98 or TA 1537, were tested. The response was positive with and without activation (Harlan, 2010).
In a Mammalian Cell Gene Mutation Assay, conducted according to
OECD Test Guideline 476 and in compliance with GLP, the test substance
was positive with and without activation in mouse lymphoma L5178Y cells
(Dow Corning Corporation, 1999).
In a Mammalian Chromosome Aberration Test, conducted according to OECD
Test Guideline 473 and in compliance with GLP, the test substance was
positive in peripheral human lymphocytes (WIL, 2015).
Link to relevant study records
- Endpoint:
- in vitro gene mutation study in bacteria
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2010-05-19 to 2010-05-25
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 471 (Bacterial Reverse Mutation Assay)
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- bacterial reverse mutation assay
- Target gene:
- histidine operon (for the Salmonella strains), tryptophan operon (for the E.coli strain)
- Species / strain / cell type:
- S. typhimurium TA 1535, TA 1537, TA 98 and TA 100
- Species / strain / cell type:
- E. coli WP2 uvr A
- Metabolic activation:
- with and without
- Metabolic activation system:
- phenobarbital/beta-napthoflavone induced rat liver S9
- Test concentrations with justification for top dose:
- 3, 10, 33, 100, 333, 1000, 2500, 5000 μg/plate
- Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: methanol
- Justification for choice of solvent/vehicle: solubility properties and relative nontoxicity to the bacteria - Untreated negative controls:
- yes
- Remarks:
- untreated
- Negative solvent / vehicle controls:
- yes
- Remarks:
- methanol
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- sodium azide
- Remarks:
- TA 1535, TA 100 (without metabolic activation)
- Untreated negative controls:
- yes
- Remarks:
- untreated
- Negative solvent / vehicle controls:
- yes
- Remarks:
- methanol
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 4-nitro-o-phenylene-diamine, 4-NOPD
- Remarks:
- TA 1537, TA 98 (without metabolic activation)
- Untreated negative controls:
- yes
- Remarks:
- untreated
- Negative solvent / vehicle controls:
- yes
- Remarks:
- methanol
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- methylmethanesulfonate
- Remarks:
- WP2 uvr A (without metabolic activation)
- Untreated negative controls:
- yes
- Remarks:
- untreated
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 2-aminoanthracene, 2-AA
- Remarks:
- all strains (with metabolic activation)
- Details on test system and experimental conditions:
- ACTIVATION: The amount of S9 supernatant was 10% v/v in the cultures. Cofactors were added to the S9 mix to reach the following concentrations in the S9 mix:
8 mM MgCl2
33 mM KCl
5 mM Glucose-6-phosphate
4 mM NADP
in 100 mM sodium-ortho-phosphate-buffer, pH 7.4
METHOD OF APPLICATION: in agar (plate incorporation)
DURATION
-After solidification, the plates were incubated upside down for 48-72 hours at 37°C in the dark
SELECTION AGENT (mutation assays): histidine-deficient agar (Salmonella strains); tryptophan-deficient agar (E.coli strain)
NUMBER OF REPLICATIONS: 3
DETERMINATION OF CYTOTOXICITY: Toxicity of the test item results in a reduction in the mean number of spontaneous revertants (> 50% reduction) or a reduction of the bacterial background lawn, in comparison to the solvent control. - Evaluation criteria:
- A test item is considered as a mutagen is a biologically relevant increase in the mean number of revertants exceeding the threshold of twice (strains TA 98, TA 100 and WP2 uvr A) or thrice (strains TA 1535 and TA 1537) the mean colony count of the corresponding solvent control is observed.
A dose dependent increase is considered biologically relevant if the threshold is exceeded at more than one concentration.
An increase exceeding the threshold at only one concentration is judged as biologically relevant if reproduced in an independent second experiment. - Statistics:
- No statistical evaluation of the data was required.
- Key result
- Species / strain:
- bacteria, other: TA 1535, TA 100, WP2 uvr A
- Metabolic activation:
- with and without
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- not applicable
- Positive controls validity:
- valid
- Key result
- Species / strain:
- S. typhimurium, other: TA 1537, TA 98
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity nor precipitates, but tested up to recommended limit concentrations
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Conclusions:
- In a valid bacterial reverse mutation assay, conducted according to OECD Test Guideline 471 and in compliance with GLP, reaction mass of 3-(2,3-epoxypropoxy)propyltrimethoxysilane and triacetoxyvinylsilane was tested using Salmonella typhimurium TTA 100, TA 1535, TA 98 or TA 1537 and E. coli WP2 uvr A. A substantial and dose dependent increase in the number of revertants was observed with or without metabolic activation in Salmonella typhimurium strains TA 100, TA 1535 an d E. coli WP2 uvr A when tested up to limit concentrations. No evidence of a test-substance related increase in the number of revertants was observed with or without metabolic activation in Salmonel la typhimurium strains TA 98 or TA 1537. Appropriate positive and solvent controls were included and gave the expected results. It is concluded that the test substance is positive for mutagenicity to bacteria under the conditions of the test.
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
- Species / strain / cell type:
- lymphocytes: Peripheral human lymphocytes
- Additional strain / cell type characteristics:
- not applicable
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9
- Test concentrations with justification for top dose:
- Without S9-mix: 100, 250, 500, 750, 1000 and 1500 µg/ml culture medium (3 h exposure time, 24 h fixation time).
With S9-mix: 500, 1000, 1500, 2000, 2500 and 3000 µg/ml culture medium (3 h exposure time, 24 h fixation time). - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- (DMSO)
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- mitomycin C
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium
DURATION
- Preincubation period: Lymphocytes were cultured for 48 ± 2 h
- Exposure duration: The lymphocytes were exposed in duplicate to selected doses of the test substance for 3 h in the absence and presence of S9-mix
- Fixation time (start of exposure up to fixation or harvest of cells): 24 h
SPINDLE INHIBITOR (cytogenetic assays): colchicine (0.5 µg/ml medium)
STAIN (for cytogenetic assays): 5% (v/v) Giemsa (Merck) solution in Sörensenbuffer pH 6.8
NUMBER OF REPLICATIONS: At least three analysable concentrations were used for scoring of the cytogenetic assay. Chromosomes of metaphase spreads were analysed from those cultures with an inhibition of the mitotic index of 55 ± 5%, whereas the mitotic index of the lowest dose level was approximately the same as the mitotic index of the solvent control. Also cultures treated with an intermediate dose were examined for chromosome aberrations.
NUMBER OF CELLS EVALUATED: The mitotic index of each culture was determined by counting the number of metaphases from at least 1000 cells (with a maximum deviation of 5%). One hundred and fifty metaphase chromosome spreads per culture were examined by light microscopy for chromosome aberrations. In case the number of aberrant cells, gaps excluded, was ≥ 38 in 75 metaphases, no more metaphases were examined. Only metaphases containing 46 ± 2 centromeres (chromosomes) were analysed. The number of cells with aberrations and the number of aberrations were calculated.
DETERMINATION OF CYTOTOXICITY
- Method: Cytotoxicity of the test substance in the lymphocyte cultures was determined using the mitotic index. No precipitation was observed in the culture medium up to the highest dose level of 5000 µg/ml. - Evaluation criteria:
- A test substance is considered positive (clastogenic) in the chromosome aberration test if:
a) At least one of the test concentrations exhibits a statistically significant (Fisher’s exact test, one-sided, p < 0.05) increase compared with the concurrent negative control.
b)The increase is dose-related when evaluated with the Cochran Armitage trend test.
c)Any of the results are outside the 95% control limits of the historical control data range.
A test substance is considered negative (not clastogenic) in the chromosome aberration test if:
a) None of the test concentrations exhibits a statistically significant (Fisher’s exact test, one-sided,
p < 0.05) increase compared with the concurrent negative control.
b)All results are inside the 95% control limits of the negative historical control data range.
In case the Fisher’s exact test shows that there are statistically significant differences between one or more of the test substance groups and the vehicle control group a Cochran Armitage trend test (p < 0.05) will be performed to test whether there is a significant trend in the induction. - Key result
- Species / strain:
- lymphocytes: periferal human lymphocytes
- Metabolic activation:
- with and without
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- Appropriate toxicity was reached at 1000 (42% MI) and 2000 (45% MI) ug/ml for 3h/24h fixation (with and without MA)- omit precipitation
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- RANGE-FINDING/SCREENING STUDIES: A concentration of 5000 µg/mL showed no precipitation in the culture medium. Therefore, a concentration of 5000 µg/mL was used as the highest concentration of the test substance. In the dose range finding test blood cultures were treated with 52, 164, 512, 1600 and 5000 µg/mL culture medium with and without S9-mix.
Based on the results of the dose range finding test the following dose levels were selected for the cytogenetic assay:
Without S9-mix: 100, 250, 500, 750, 1000 and 1500 µg/mL culture medium (3 h exposure time, 24 h fixation time).
With S9-mix: 500, 1000, 1500, 2000, 2500 and 3000 µg/mL culture medium (3 h exposure time, 24 h fixation time).
COMPARISON WITH HISTORICAL CONTROL DATA: The number of cells with chromosome aberrations found in the solvent control cultures was within the laboratory historical control data range.
ADDITIONAL INFORMATION ON CYTOTOXICITY: A concentration of 5000 µg/mL showed no precipitation in the culture medium. Therefore, a concentration of 5000 µg/mL was used as the highest concentration of the test substance. In the dose range finding test blood cultures were treated with 52, 164, 512, 1600 and 5000 µg/mL culture medium with and without S9-mix. The pH was determined for all concentrations. - Conclusions:
- In a Mammalian Chromosome Aberration Test, conducted according to OECD Test Guideline 473 and in compliance with GLP, the test substance was positive in peripheral human lymphocytes. The test substance induced a statistically significant, dose dependent increase in the number of cells with chromosome aberrations both when gaps were included and excluded in the cytogenetic assay. The test substance did not increase the number of polyploid cells and cells with endoreduplicated chromosomes. Appropriate solvent, negative (cell culture medium) and positive controls were included and gave expected results. It is concluded that Reaction mass of 3-(2,3-epoxypropoxy)propyltrimethoxysilane and triacetoxyvinylsilane is positive for chromosomal aberrations to mammalian cells under the conditions of the test.
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1999-08-18 to 1999-10-20
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Version / remarks:
- 1997
- Deviations:
- no
- GLP compliance:
- yes
- Type of assay:
- mammalian cell gene mutation assay
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Metabolic activation system:
- Aroclor induced rat liver S9
- Test concentrations with justification for top dose:
- Without metaboilc activation: 250, 375, 500, 750 μg/ml. With metabolic activation: 500, 750, 1000, 1500 μg/ml
- Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: DMSO
- Justification for choice of solvent/vehicle: Chosen on advice from sponsor. Historical data were available to demonstrate that DMSO causes no deleterious or mutagenic effects. - Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- methylmethanesulfonate
- Remarks:
- without activation
- Untreated negative controls:
- no
- Negative solvent / vehicle controls:
- yes
- True negative controls:
- no
- Positive controls:
- yes
- Positive control substance:
- other: 20-methylcholanthrene
- Remarks:
- with activation
- Details on test system and experimental conditions:
- METHOD OF APPLICATION: in medium; in agar; in suspension
DURATION
- Exposure duration: 3 hours
- Expression time (cells in growth medium): 48 hours
- Selection time (if incubation with a selection agent): 12 days
- Fixation time (start of exposure up to fixation or harvest of cells): 51 hours
SELECTION AGENT (mutation assays): Cloning medium (R30p) with 4 μg/ml TFT (Sigma)
NUMBER OF REPLICATIONS: 3 plates per concentration
NUMBER OF CELLS EVALUATED: 10(6) cells
DETERMINATION OF CYTOTOXICITY
- Method: cloning efficiency; relative total growth
- Evaluation criteria:
- A result would be positive if the following were shown:
An increase in mutant frequency in treated cultures of at least 100 relative to the concurrent control.
A statistically significant increase in mutant frequency
Evidence of a dose relationship over at least 2 dose levels
Demonstration of reproducibility in any increase in mutant frequency
An increase in absolute mutant colony numbers in treated cultures
The RTG of cultures showing an increase in mutant frequency should not be less than 10 % - Statistics:
- Growth in suspension was calculated as follows:
Cell count 24 hours post treatment / 2 x 105 x Cell count 48 hours post treatment / 2* x 105
* or previous day’s cell count if less than 2 x 105 per ml
Relative total growth over the experimental period was estimated from the following equation:-
RTG = Suspension growth (% control) x Plating efficiency in agar (% control) / 100
Mutant frequency was calculated from:-
MF = 600 / Total no. of viable colonies x Total no. of mutant colonies / 3
Statistical significance was analysed by weighted analysis of variance as described by Arlett et al (1989). - Key result
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- positive
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
- Conclusions:
- In a Mammalian Cell Gene Mutation Assay, conducted according to OECD Test Guideline 476 and in compliance with GLP, the reaction mass of 3-(2,3-epoxypropoxy)propyltrimethoxysilane and triacetoxyvinylsilane showed a clear, statistically significant evidence of a dose-dependent increase in frequency of revertants with and without activation up to cytotoxic concentrations. Consequently, the test substance is considered mutagenic in mouse lymphoma L5178Y cells under the conditions of the test.
Referenceopen allclose all
Table 1: Plate incorporation test: Mean number of revertants per plate (3 plates)
Dose (µg/plate) |
TA 1535 |
TA 1537 |
TA 98 |
TA 100 |
WP2 uvr A |
|||||
- MA |
+ MA |
- MA |
+ MA |
- MA |
+ MA |
- MA |
+ MA |
- MA |
+ MA |
|
3 |
14 |
29 |
10 |
14 |
26 |
36 |
118 |
124 |
39 |
49 |
10 |
18 |
22 |
9 |
16 |
24 |
41 |
101 |
122 |
42 |
46 |
33 |
20 |
24 |
10 |
16 |
27 |
38 |
118 |
129 |
43 |
52 |
100 |
33 |
33* |
8 |
15* |
28 |
37 |
123 |
128 |
44 |
50 |
333 |
73 |
72* |
9 |
18* |
27 |
43* |
155 |
132* |
45 |
56* |
1000 |
133 |
151* |
14 |
18* |
25 |
37* |
214 |
193* |
63 |
57* |
2500 |
242 |
270* |
11 |
13* |
23 |
35* |
374 |
283* |
83 |
64* |
5000 |
404 |
407* |
14 |
15* |
25 |
38* |
662 |
511* |
129 |
105* |
Untreated |
16 |
19 |
9 |
19 |
27 |
45 |
121 |
127 |
44 |
55 |
Solvent control (methanol) |
14 |
17 |
9 |
19 |
28 |
40 |
117 |
126 |
40 |
48 |
Positive control (NaN3) - 10 |
1516 |
- |
- |
- |
- |
- |
1608 |
- |
- |
- |
Positive control (4-NOPD) - 10 |
- |
- |
- |
- |
336 |
- |
- |
- |
- |
- |
Positive control (4-NOPD) - 50 |
- |
- |
66 |
- |
- |
- |
- |
- |
- |
- |
Positive control (MMS) - 3 |
- |
- |
- |
- |
- |
- |
- |
- |
749 |
- |
Positive control (2-AA) - 2.5 |
- |
221 |
- |
455 |
- |
2224 |
- |
3198 |
- |
- |
Positive control (2-AA) - 10 |
- |
- |
- |
- |
- |
- |
- |
- |
- |
270 |
* Reduced background growth
NaN3 = sodium azide
2 -AA = 2 -aminoanthracene
4 -NOPD = 4 -nitro-o-phenylene-diamine
MMS = methyl methane sulfonate
Table 6: Chromosome aberrations in human lymphocyte cultures treated with the test substance in the absence of S9-mix in the first cytogenetic assay (3 h exposure time, 24 h fixation time)
Concentration |
Solvent control DMSO 1.0 % v/v |
Low dose 100µg/ml |
Mid dose 500µg/ml |
High dose 1000µg/ml |
MMC-C 0.5µg/ml |
|
No of cells |
150 150 300 |
150 150 300 |
150 150 300 |
150 150 300 |
75 75 150 |
|
Culture |
A B A+B |
A B A+B |
A B A+B |
A B A+B |
A B A+B |
|
Chromatid aberrations |
gaps |
1 |
1 |
1 1 |
1 1 |
|
breaks |
3 |
1 1 |
4 5 |
50 48 |
15 26 |
|
intrachanges |
|
|
|
Intra intra |
2intra 3intra |
|
Chromosome aberrations |
gaps |
|
|
1 |
1 1 |
1 1 |
breaks |
3 |
2 |
2 3 |
9 7 |
12 10 |
|
intrachanges |
|
|
|
Intra intra |
2intra 3intra |
|
Mitotic index |
100 |
93 |
66 |
42 |
64 |
|
Polyploidy |
0 |
0 |
0 |
0 |
0 |
|
Endo reduplication |
|
|
1 |
1 |
|
Table 7: Chromosome aberrations in human lymphocyte cultures treated with the test substance in the presence of S9-mix in the first cytogenetic assay (3 h exposure time, 24 h fixation time)
Concentration |
Solvent control DMSO 1.0 % v/v |
Low dose 500µg/ml |
Mid dose 1000µg/ml |
High dose 2000µg/ml |
CP 10µg/ml |
|
No of cells |
150 150 300 |
150 150 300 |
150 150 300 |
150 150 300 |
150 75 225 |
|
Culture |
A B A+B |
A B A+B |
A B A+B |
A B A+B |
A B A+B |
|
Chromatid aberrations |
gaps |
1 |
1 |
1 3 |
1 |
|
breaks |
1 1 |
13 8 |
7 11 |
53 36 |
32 36 |
|
intrachanges |
|
|
|
Intra intra |
2intra |
|
Chromosome aberrations |
gaps |
|
|
1 1 |
1 |
1 1 |
breaks |
|
5 2 |
5 2 |
12 14 |
8 9 |
|
intrachanges |
|
|
|
Intra intra |
2intra |
|
Mitotic index |
100 |
81 |
69 |
45 |
56 |
|
Polyploidy |
0 |
1 |
0 |
0 |
0 |
|
Endo reduplication |
0 |
1 |
0 |
0 |
0 |
Table 2: Results of Mammalian Mutagenicity assay (Test 1) with tester strain L5178Y (mean of 3 plates)
Concentration µg/ml |
Mutant* Frequency |
Relative total growth (mean % of control) |
Cytotoxicity |
|||
- |
— MA |
+ MA |
— MA |
+ MA |
— MA |
+ MA |
Solvent Control** |
163 |
181 |
100 |
100 |
No |
No |
250 |
286 |
- |
73 |
- |
No |
- |
375 |
469 |
- |
47 |
- |
Yes |
- |
500 |
541 |
272 |
44 |
90 |
Yes |
No |
750 |
1304 |
163 |
13 |
50 |
Yes |
Yes |
1000 |
- |
649 |
- |
37 |
- |
Yes |
1500 |
- |
1328 |
- |
11 |
- |
Yes |
Positive Control |
601 |
802 |
73 |
45 |
No |
Yes |
*Per 106surviving cells
**solvent control with DMSO
Table 3: Results of Mammalian Mutagenicity assay (Test 2) with tester strain L5178Y (mean of 3 plates)
Concentration µl/ml |
Mutant* Frequency |
Relative total growth (mean % of control) |
Cytotoxicity |
|||
- |
— MA |
+ MA |
— MA |
+ MA |
— MA |
+ MA |
Solvent Control** |
148 |
152 |
100 |
100 |
No |
No |
187.5 |
192 |
- |
83 |
- |
No |
- |
250 |
246 |
- |
47 |
- |
Yes |
- |
375 |
315 |
- |
44 |
- |
Yes |
- |
500 |
451 |
236 |
35 |
96 |
Yes |
No |
750 |
767 |
336 |
15 |
71 |
Yes |
No |
1000 |
- |
547 |
- |
51 |
- |
Yes |
1500 |
- |
962 |
- |
26 |
- |
Yes |
Positive Control |
754 |
840 |
46 |
40 |
Yes |
Yes |
*Per 106surviving cells
**solvent control with DMSO
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (positive)
Genetic toxicity in vivo
Endpoint conclusion
- Endpoint conclusion:
- no study available (further information necessary)
Additional information
Information is available from reliable studies for all the required in vitro endpoints. The results of all of the studies were in agreement. There was evidence for mutagenicity and clastogenicity (causing chromosomal aberrations) in the presence and absence of metabolic activation in vitro.
In a valid bacterial reverse mutation assay, conducted according to OECD Test Guideline 471 and in compliance with GLP, Reaction Products of 3-(2,3-epoxypropoxy)propyltrimethoxysilane and triacetoxy(vinyl)silane was tested using Salmonella typhimurium TA 100, TA 1535, TA 98, TA 1537 and E. coli WP2 uvr A. A substantial and dose dependent increase in the number of revertants was observed with or without metabolic activation in Salmonella typhimurium strains TA 100, TA 1535 an d E. coli WP2 uvr A when tested up to limit concentrations. No evidence of a test-substance related increase in the number of revertants was observed with or without metabolic activation in Salmonella typhimurium strains TA 98 or TA 1537. Appropriate positive and solvent controls were included and gave the expected results. It is concluded that the test substance is positive for mutagenicity to bacteria under the conditions of the test (Dow Corning Corporation, 2010).
In a Mammalian Cell Gene Mutation Assay, conducted according to OECD Test Guideline 476 and in compliance with GLP, the Reaction Products of 3-(2,3-epoxypropoxy)propyltrimethoxysilane and triacetoxy(vinyl)silane showed a clear, statistically significant evidence of a dose-dependent increase in frequency of revertants with and without activation up to cytotoxic concentrations. Consequently, the test substance is considered mutagenic in mouse lymphoma L5178Y cells under the conditions of the test (Dow Corning Corporation, 1999).
In a Mammalian Chromosome Aberration Test, conducted according to OECD Test Guideline 473 and in compliance with GLP, the test substance was positive in peripheral human lymphocytes. The test substance induced a statistically significant, dose dependent increase in the number of cells with chromosome aberrations both when gaps were included and excluded in the cytogenetic assay. The test substance did not increase the number of polyploid cells and cells with endoreduplicated chromosomes. Appropriate solvent, negative (cell culture medium) and positive controls were included and gave expected results. It is concluded that Reaction Products of 3-(2,3-epoxypropoxy)propyltrimethoxysilane and triacetoxy(vinyl)silane is positive for chromosomal aberrations to mammalian cells under the conditions of the test (WIL, 2015).
In a supporting bacterial mutagenicity study, conducted according to OECD Test Guideline 471 and in compliance with GLP, reaction products of 3-(2,3-epoxypropoxy)propyltrimethoxysilane and triacetoxy(vinyl)silane caused dose-related increases in the number of revertants in both the presence and absence of metabolic activation in Salmonella typhimurium strains TA 100 and TA 1535 in the initial and the repeat experiments up to cytotoxic/limit concentrations. No evidence of a test-substance related increase in the number of revertants was observed in the presence or absence of metabolic activation in Salmonella typhimurium strains TA 98, TA 1537 or E.coli strain WP2 uvrA pKM 101. Appropriate positive and solvent controls were included and gave the expected results. It is concluded that the test substance is positive for mutagenicity to bacteria under the conditions of the test (Dow Corning Corporation, 1999).
In a supporting bacterial mutagenicity study, conducted according to OECD Test Guideline 471 and in compliance with GLP, reaction products of 3-(2,3-epoxypropoxy)propyltrimethoxysilane and triacetoxy(vinyl)silane caused a substantial and dose dependent increase in the number of revertants in the presence and absence of metabolic activation in Salmonella typhimurium strains TA 100, TA 1535 and E. coli WP2 uvrA when tested up to limit concentrations. No evidence of a test-substance related increase in the number of revertants was observed in the presence or absence of metabolic activation in Salmonella typhimurium strains TA 98 or TA 1537. Appropriate positive and solvent controls were included and gave the expected results. It is concluded that the test substance is positive for mutagenicity to bacteria under the conditions of the test (Dow Corning Corporation, 2010).
The results of all in vitro bacterial mutagenicity studies, in vitro mammalian mutagenicity (MLA) studies and in vitro cytogenicity study were in agreement, and demonstrated clear evidence of mutagenicity.
For all of the in vitro bacterial mutagenicity studies, positive results were obtained for bacterial strains TA-1535, TA-100 in all studies, and for WP2 uvRA in two out of three studies, which are indicative of base pair substitution (TA-1535, TA-100) and cross-linking mutations (WP2 uvRA). In addition, the test substance was positive in the L5178Y TK+/- MLA test for mutagenicity. The results included an indication of clastogenic potential with the presence of small colonies generated. Furthermore, the test substance was positive in the in vitro cytogenicity study which included significant chromosomal damage to the levels of chromatid breaks, whole chromosome breaks, and exchange-type aberrations.
The results from the above in vitro studies also demonstrate dose-responsiveness, reproducibility, and the assays were conducted with the suitable solvents up to appropriate levels of toxicity.
Also, from a structural alert standpoint, this substance contains a structure with an epoxide equivalent molecular weight present at <1000 which poses a human health concern for carcinogenic potential.
There is no existing in vivo study or TK data available. In view of the positive results in mammalian cells in vitro, the Lead Registrant proposes to conduct an in vivo micronucleus assay (with bioavailability) combined with a comet assay (OECD 474 treatment option c with OECD 489) as it can detect evidence of chromosome damage/clastogenicity and DNA damage that may lead to somatic or heritable gene mutations.
If the in vivo micronucleus assay results in a positive response, the comet assay would enable it to be demonstrated whether the substance reacts directly with DNA in site of contact tissues and following systemic exposure.
If the micronucleus assay results in a negative response, a conclusion on somatic cell mutagenicity could be reached from the result of the comet assay.
Although it is generally assumed that somatic assays are sufficient to protect the germ cell line, if the results of the micronucleus and comet assays indicate that this is something that needs investigation, then the Transgenic rodent assay will be considered and may be added to the testing regimen.
Justification for classification or non-classification
More information required before final decision can be made for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.